share_log

Vertex Pharmaceuticals | SC TO-T/A: Third party tender offer statement (Amendment)

Vertex Pharmaceuticals | SC TO-T/A: Third party tender offer statement (Amendment)

福泰制药 | SC TO-T/A：发行招标公告
美股sec公告 ·  05/08 08:58
Moomoo AI 已提取核心信息
Vertex Pharmaceuticals Incorporated, through its wholly owned subsidiary Adams Merger Sub, Inc., has announced a tender offer to acquire all issued and outstanding shares of Alpine Immune Sciences, Inc. at a price of $65.00 per share in cash. The offer, detailed in an amendment to the Schedule TO filed with the SEC on April 22, 2024, is set to expire at 11:59 p.m. ET on May 17, 2024, unless extended. The amendment supplements previous disclosures, including the expected filing of Premerger Notification and Report Forms under the HSR Act by April 24, 2024, and provides additional information on the background of the offer and regulatory approvals. The offer's terms and conditions, including the potential extension of the expiration time, are outlined in the Offer to Purchase. Vertex has also filed related materials with the SEC, including a press release and excerpts from their Q1 earnings call on May 6, 2024.
Vertex Pharmaceuticals Incorporated, through its wholly owned subsidiary Adams Merger Sub, Inc., has announced a tender offer to acquire all issued and outstanding shares of Alpine Immune Sciences, Inc. at a price of $65.00 per share in cash. The offer, detailed in an amendment to the Schedule TO filed with the SEC on April 22, 2024, is set to expire at 11:59 p.m. ET on May 17, 2024, unless extended. The amendment supplements previous disclosures, including the expected filing of Premerger Notification and Report Forms under the HSR Act by April 24, 2024, and provides additional information on the background of the offer and regulatory approvals. The offer's terms and conditions, including the potential extension of the expiration time, are outlined in the Offer to Purchase. Vertex has also filed related materials with the SEC, including a press release and excerpts from their Q1 earnings call on May 6, 2024.
Vertex Pharmicals Incorporated通过其全资子公司Adams Merger Sub, Inc. 宣布要约以每股65.00美元的现金价格收购Alpine Immune Sciences, Inc.的所有已发行和流通股份。该提议将在2024年4月22日向美国证券交易委员会提交的附表TO修正案中详细说明，除非延期，否则将于美国东部时间2024年5月17日晚上 11:59 到期。该修正案补充了先前的披露，包括预计在2024年4月24日之前根据HSR法案提交合并前通知和报告表，并提供了有关要约背景和监管部门批准的更多信息。购买要约中概述了该优惠的条款和条件，包括可能的到期时间延长。Vertex还向美国证券交易委员会提交了相关材料，包括新闻稿和2024年5月6日第一季度财报电话会议的摘录。
Vertex Pharmicals Incorporated通过其全资子公司Adams Merger Sub, Inc. 宣布要约以每股65.00美元的现金价格收购Alpine Immune Sciences, Inc.的所有已发行和流通股份。该提议将在2024年4月22日向美国证券交易委员会提交的附表TO修正案中详细说明，除非延期，否则将于美国东部时间2024年5月17日晚上 11:59 到期。该修正案补充了先前的披露，包括预计在2024年4月24日之前根据HSR法案提交合并前通知和报告表，并提供了有关要约背景和监管部门批准的更多信息。购买要约中概述了该优惠的条款和条件，包括可能的到期时间延长。Vertex还向美国证券交易委员会提交了相关材料，包括新闻稿和2024年5月6日第一季度财报电话会议的摘录。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息